Cargando…

Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is an important risk factor in patients with CKD, and some medications for treating CKD-MBD have been recently marketed. Because assessment of health-care cost-effectiveness is growing in importance with increases in health expenditures, sev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goto, Shunsuke, Komaba, Hirotaka, Fukagawa, Masafumi, Nishi, Shinichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089630/ https://www.ncbi.nlm.nih.gov/pubmed/25019030 http://dx.doi.org/10.1038/kisup.2013.95

Ejemplares similares

Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention
por: Goto, Shunsuke, et al.
Publicado: (2008)

Newly Developed Rat Model of Chronic Kidney Disease–Mineral Bone Disorder
por: Watanabe, Kentaro, et al.
Publicado: (2018)

Introduction: expanding concepts of chronic kidney disease-mineral and bone disorder (CKD-MBD)
por: Fukagawa, Masafumi, et al.
Publicado: (2013)

Renin-Angiotensin System Inhibitors Reduce Serum Asymmetric Dimethylarginine Levels and Oxidative Stress in Normotensive Patients with Chronic Kidney Disease
por: Fujii, Hideki, et al.
Publicado: (2014)

Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction
por: Fujii, Hideki, et al.
Publicado: (2018)

Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine
por: Komaba, Hirotaka, et al.
Publicado: (2021)

Mineral and bone disorder management in hemodialysis patients: comparing PTH control practices in Japan with Europe and North America: the Dialysis Outcomes and Practice Patterns Study (DOPPS)
por: Yamamoto, Suguru, et al.
Publicado: (2018)

Marked increase in bone formation markers after cinacalcet treatment by mechanisms distinct from hungry bone syndrome in a haemodialysis patient
por: Goto, Shunsuke, et al.
Publicado: (2010)

Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease: a report of three cases
por: Komaba, Hirotaka, et al.
Publicado: (2008)

A Retrospective Study on Erythropoiesis Stimulating Agent Dose Reducing Potential of an Anti‐Platelet Activation Membrane Dialyzer in Hemodialysis Patients
por: Kakuta, Takatoshi, et al.
Publicado: (2018)

Acute cardiac overload does not induce cardiac or skeletal expression of fibroblast growth factor 23 in rats
por: Fajol, Abul, et al.
Publicado: (2021)

TGF-Beta Signaling in Bone with Chronic Kidney Disease
por: Iwasaki, Yoshiko, et al.
Publicado: (2018)

Response to Letter to the Editor From Sumi et al: “Lower Bone Turnover and Skeletal PTH Responsiveness in Japanese Compared to European Patients Receiving Hemodialysis”
por: Jørgensen, Hanne Skou, et al.
Publicado: (2022)

Chronic Kidney Disease-Mineral and Bone Disorder
por: Lee, Wen-Chin, et al.
Publicado: (2017)

Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease
por: Iwasaki, Yoshiko, et al.
Publicado: (2017)

Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

The Pituitary Is a Candidate Organ That Modulates Circulating Klotho Levels
por: Sato, Tetsuhiko, et al.
Publicado: (2018)

Biopsy-proven CKD etiology and outcomes: the Chronic Kidney Disease Japan Cohort (CKD-JAC) study
por: Hamano, Takayuki, et al.
Publicado: (2022)

Chronic kidney disease mineral and bone disorder in children
por: Wesseling, Katherine, et al.
Publicado: (2007)

Role of Chronic Kidney Disease (CKD)–Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD
por: Yamada, Shunsuke, et al.
Publicado: (2023)

Association between serum iron markers, iron supplementation and cardiovascular morbidity in pre-dialysis chronic kidney disease
por: Hasegawa, Takeshi, et al.
Publicado: (2023)

The Modified Chronic Kidney Disease Epidemiology Collaboration Equation for the Estimated Glomerular Filtration Rate Is Better Associated with Comorbidities than Other Equations in Living Kidney Donors in Japan
por: Nishi, Shinichi, et al.
Publicado: (2021)

Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review
por: Komaba, Hirotaka, et al.
Publicado: (2008)

Roles of PTH and FGF23 in kidney failure: a focus on nonclassical effects
por: Komaba, Hirotaka
Publicado: (2023)

Update of Brazilian Guidelines for Treatment and Assessment of Chronic Kidney Disease – Mineral and Bone Disorders
por: Carvalho, Aluízio Barbosa, et al.
Publicado: (2021)

Artificial intelligence–guided precision treatment of chronic kidney disease–mineral bone disorder
por: Gaweda, Adam E., et al.
Publicado: (2022)

Influence of oxidative stress on vascular calcification in the setting of coexisting chronic kidney disease and diabetes mellitus
por: Watanabe, Shuhei, et al.
Publicado: (2020)

Which Outcome in Chronic Kidney Disease-Mineral and Bone Disorder Patients?
por: Cozzolino, Mario
Publicado: (2014)

Mouse Models of Mineral Bone Disorders Associated with Chronic Kidney Disease
por: Zaloszyc, Ariane, et al.
Publicado: (2023)

Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy
por: Okamoto, Kohei, et al.
Publicado: (2021)

The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

Bone matrix mineralization and osteocyte lacunae characteristics in patients with chronic kidney disease - mineral bone disorder (CKD-MBD)
por: Misof, Barbara M., et al.
Publicado: (2019)

Potential therapeutic interventions for chronic kidney disease‐associated sarcopenia via indoxyl sulfate‐induced mitochondrial dysfunction
por: Enoki, Yuki, et al.
Publicado: (2017)

Mineral and Bone Disorders After Kidney Transplantation
por: Vangala, Chandan, et al.
Publicado: (2018)

Renal protective effects of astragalus root in rat models of chronic kidney disease
por: Goto, Shunsuke, et al.
Publicado: (2023)

Early chronic kidney disease-mineral bone disorder stimulates vascular calcification
por: Fang, Yifu, et al.
Publicado: (2013)

A New Murine Model of Chronic Kidney Disease-Mineral and Bone Disorder
por: Frauscher, Bianca, et al.
Publicado: (2017)

Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD): Current Perspectives
por: Waziri, Bala, et al.
Publicado: (2019)

Role of Calcimimetics in Treating Bone and Mineral Disorders Related to Chronic Kidney Disease
por: Hou, Yi-Chou, et al.
Publicado: (2022)

The current status of chronic kidney disease-mineral and bone disorder management in China
por: Zhan, Ya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rnff2foov2k4rrvfntt2gub5a4